Delivery Order SPE2DB24D9222-SPE2DB25FAZLD
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. The award was issued on April 24, 2025, with an ultimate completion date of April 25, 2025, and carries no set-aside designation. This delivery order represents a discrete pharmaceutical supply transaction under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units) with a ceiling value of $8,339.18. This firm fixed-price delivery order, issued on September 11, 2025, with ultimate completion by September 12, 2025, represents a routine pharmaceutical supply transaction under DMS Pharmaceutical Group's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on May 30, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The award, effective through June 2, 2025, carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its Park Ridge location. The company has been registered in the System for Award...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, was issued without a set-aside designation. The award represents a single delivery order issued under DMS...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. on September 9, 2025, for the supply of Xtandi 40 mg tablets (120-count units). DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this order at its Park Ridge location with an ultimate completion date of September 10, 2025. This delivery order was issued without a set-aside designation,...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg tablets (120-count). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge facility. This delivery order was awarded without set-aside designation on September 18, 2025, with an ultimate completion date of September 19, 2025. This award is...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count packaging). This firm fixed-price delivery order, valued at $4,169.59, was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a time-sensitive pharmaceutical procurement fulfilling military healthcare supply requirements. The award...
- SPE2DB24D9222Indefinite Delivery Contract
- SPE2DB24D9222-SPE2DB25FAZLDDelivery Order
The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order, issued on September 24, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation and leverages DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program. The award reflects the agency's procurement of oncology pharmaceuticals to support Department of Defense healthcare facilities and military medical supply chains. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical distribution network, with a robust portfolio of delivery orders covering a comprehensive range of medications and medical consumables. The company's underlying IDC with the DLA, valued at $499,999,999 and valid through November 2026, enables the agency to issue firm fixed-price orders for branded and generic prescription drugs, biologics, and specialty pharmaceuticals across various therapeutic categories. This particular delivery order for Xtandi exemplifies the company's continued role in supplying specialty cancer medications and other essential pharmaceutical products to federal healthcare systems nationwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 9/24/25 |